SS2012 Clinical Science Description grid by bm69jY9

VIEWS: 2 PAGES: 4

									 CLINICAL SCIENCE: SPECIAL REPORTS DESCRIPTIONS
                                      MONDAY
CS.01 Clinical Science: Special Reports – Prevention and Treatment of Ischemic Heart
Disease: Novel Approaches                                  (Petree Hall D)
  Embargo/      Presenter       Title                           Description
Presentation
     Time
7:30 a.m. PT,    Stephan M Nidorf,      Low Dose Colchicine for            The LoDoCo trial was designed to determine whether
                 Health Care WA,        Secondary Prevention of            colchicine given in addition to standard medical
Monday, Nov. 5   Perth, Australia       Cardiovascular Disease             therapy is effective for the prevention of major
                                                                           cardiovascular endpoints in patients with stable
                                                                           coronary artery disease.

7:49 a.m. PT,    Wei Jiang,             Results of the Responses of        This trial examines the effects of escitalopram, a
                 Duke Univ. Med. Ctr,   Myocardial Ischemia to             selective serotonin reuptake inhibitor (SSRI), on
Monday, Nov. 5   Durham, NC             Escitalopram Treatment Trial       mental stress –induced myocardial ischemia (MSIMI)
                                                                           in coronary heart disease patients.
8:08 a.m. PT,    L Kristin Newby,       SOLSTICE (Study Of LoSmapimod      This is a randomized, double-blind, placebo-
                 Duke Univ. Med Ctr ,   Treatment on Inflammation and      controlled, parallel group, multicenter, phase 2a
Monday, Nov. 5   Durham., NC            InfarCtSizE). Results of the       study to evaluate the safety and efficacy of 12-week
                                        SOLSTICE Phase 2 Randomized        treatment with 2 dose regimens of losmapimod, a
                                        Trial.                             potent oral p38-MAPK inhibitor, versus placebo in
                                                                           patients with non-ST-segment elevation myocardial
                                                                           infarction (NSTEMI) expected to undergo an invasive
                                                                           strategy.
8:27 a.m. PT,    Vasilios               enligHTN I, First-In-Man           This study was designed to study the efficacy and
                 Papademetriou, VA      Multicenter Study of a Novel       safety of a new radio frequency ablation catheter in
Monday, Nov. 5   Med Ctr, Washington,   Multi-electrode Renal              patients with drug-resistant hypertension.
                 D.C.                   Denervation Catheter in Patients
                                        with Drug-Resistant Hypertension




 1
 CLINICAL SCIENCE: SPECIAL REPORTS DESCRIPTIONS
CS.02 Clinical Science: Special Reports – New Insights Into Management of Common
Cardiovascular Disorders                                  (Petree Hall D)
  Embargo/      Presenter       Title                            Description
Presentation
     Time
5:30 p.m. PT     David G. Jones, Royal    A Randomized Trial to Assess        This trial was designed to evaluate ablation versus rate
                 Brompton & Harefield,    Catheter Ablation versus Rate       control in management of patients with persistent
Monday, Nov. 5   Imperial Coll, London,   Control in the Management of        atrial fibrillation and heart failure.
                 UK                       Persistent Atrial Fibrillation in
                                          Chronic Heart Failure: ARC-HF
5:40 p.m. PT     Xue Zhao, Shanghai       Pulmonary Antrum Radial-            This trial examines the efficacy and safety of
                 Changzheng Hosp,         linear Ablation of Paroxysmal       pulmonary vein (PV) antrum radial-linear ablation in
Monday, Nov. 5   Second Military Med      Atrial Fibrillation: First-in-      paroxysmal AF patients.
                 Ctr, Shanghai, China     human Multicenter Clinical
                                          Outcome
5:50 p.m. PT     Hung-Fat Tse, Univ. of   Septal Pacing for Atrial            This prospective randomized study was designed to
                 Hong Kong, Hong          Fibrillation Suppression            assess the efficacy of site and rate of atrial pacing on
Monday, Nov. 5   Kong                     Evaluation (SAFE) Study.            long-term progression of atrial fibrillation in sick sinus
                                                                              syndrome.
6:10 p.m. PT     Marc Semigran,           Left Ventricular Systolic           This study was designed to assess the effects of
                 Mass. General Hosp.      Dysfunction Associated with         riociguat on hemodynamics, safety and functional
Monday, Nov. 5   Heart Ctr, Boston, MA    Pulmonary Hypertension              outcomes in heart failure patients with left ventricular
                                          Riociguat Trial (LEPHT)             dysfunction and secondary pulmonary hypertension.
6:20 p.m. PT     Mads J. Andersen,        Sildenafil and Diastolic            Sildenafil and Diastolic dysfunction after acute MZI in
                 Rigshospitalet,          Sysfunction After Acute             patients with preserved ejection fraction is a
Monday, Nov. 5                            Myocardioal Infarction in           prospective, double-blinded, placebo-controlled
                 Kobehavn O,              Patients with Preserved             randomized trial.
                 Denmark                  Ejection Fraction – (SIDAMI) -




 2
 CLINICAL SCIENCE: SPECIAL REPORTS DESCRIPTIONS
                                                  TUESDAY
CS.03 Clinical Science: Special Reports – Emerging Therapies for Diabetes and
Dyslipidemia                                                      (Petree Hall D)
  Embargo/      Presenter       Title                          Description
Presentation
     Time
7:30 a.m. PT,     Julio Rosenstock,        Impact of LX4211, a Dual        This trial was designed to evaluate the safety and
                  Dallas Diabetes &        Inhibitor of Sodium Glucose     efficacy of LX4211 in combination with metformin in
Tuesday, Nov. 6   Endocrine Ctr, Dallas,                                   subjects with type 2 diabetes mellitus who have
                                           Transporter 1 & 2 on
                  TX                       Cardiovascular Risk Factors     inadequate glycemic control on metformin
                                                                           monotherapy.
                                           in Type 2 Diabetes
7:45 a.m. PT,     Robert G. Giugliano,     LAPLACE-TIMI 57 Primary         This study was a 12-week, randomized, double-
                  Brigha.m. & Women’s      Results                         blinded, dose-ranging, placebo-controlled study
Tuesday, Nov. 6   Hosp, Boston, MA                                         designed to assess the efficacy, safety and tolerability
                                                                           of AMG 145 (a PCSK9 inhibitor) when added to statin
                                                                           therapy in patients with hypercholesterolemia.
7:55 a.m. PT,     Michael J. Koren,        Results from the MENDEL         This randomized, double-blind, placebo-and
                  Jacksonville Ctr for     Study, a Global Phase 2 Trial   ezetimibe-controlled trial was designed to evaluate
Tuesday, Nov. 6   Clinical Res,                                            the Efficacy and Safety of a Fully Human Monoclonal
                                           of AMG 145
                  Jacksonville, FL                                         Antibody Against PCSK9 (AMG 145) as Monotherapy
                                                                           for Hypercholesterolemia.
8:05 a.m. PT,     Nihar R Desai,           AMG 145, a Fully Human          This trial examines the impact of AMG 145, a fully
                  Div. of CV Med,          Monoclonal Antibody             human monoclonal antibody against proprotein
Tuesday, Nov. 6   Brigham & Women’s                                        convertase subtilisin kexin type 9 (PCSK9) on
                                           Against Proprotein
                  Hosp, Boston, MA         Convertase Subtilisin Kexin     achieving NCEP LDL-Cholesterol goals in high-risk
                                                                           patients.
                                           type 9 (PCSK9), Facilitates
                                           Achievement of NCEP LDL-
                                           Cholesterol Goals in High-
                                           Risk Patients




 3
CLINICAL SCIENCE: SPECIAL REPORTS DESCRIPTIONS
                                              WEDNESDAY
CS.04 Clinical Science: Special Reports – Valvular Heart Disease, PAD, Atrial
Fibrillation: International Perspectives                            (Petree Hall D)
  Embargo/      Presenter      Title                           Description
Presentation
    Time
10:45 p.m. PT,   K.M. John Chan,          Final Results of the                 This trial was designed to evaluate if mitral valve
                 Imperial Coll, London,   Randomized Ischemic Mitral           annuloplasty in addition to coronary artery bypass
Wednesday,       UK                                                            grafting was more beneficial in moderate functional
                                          Evaluation (RIME) Trial
Nov.7                                                                          ischemic mitral regurgitation than CABG only.



11 a.m. PT,      Masato Nakamura,         EndOVascular Treatment for           This study was designed to assess the efficacy and
                 Toho Univ, Ohashi        Intra-inguinal Vessel, in            safety of endovascular treatment for Japanese
Wednesday,       Med Ctr, Tokya, Japan                                         patients with critical limb ischemia due to
                                          Patients with Critical Limb
Nov.7                                     Ischemia (olive) Registry in         infrainguinal lesion.
                                          Japan
11:15 a.m. PT,   Mohammad Zubaid,         Management and One Year              Observational registry of atrial fibrillation
                 Faculty of Med.,         Outcome of Atrial Fibrillation       management and outcomes in the Gulf region of the
Wednesday,       Kuwait Univ, Kuwait                                           Middle East.
                                          in Middle Eastern Cohort
Nov.7            City, Kuwait             Enrolled in the Observational
                                          Gulf Survey of Atrial
                                          Fibrillation Events (Gulf
                                          SAFE)
11:25 a.m. PT,   Steven Swiryn <          Results from the Registry of         The outcome-oriented “RATE Registry” was designed
                 Northwestern Univ.,      Atrial Tachycardia and Atrial        to evaluate the clinical implications, if any, of
Wednesday,       Chicago, IL                                                   pacemaker or defibrillator-documented atrial
                                          Fibrillation Episodes in the
Nov. 7                                    Cardiac Rhythm                       fibrillation or atrial tachycardia.
                                          Management Device
                                          Population (RATE)
11:45 a.m. PT,   Ajay K Kakkar,           Antithrombotic Treatments and        This global registry gathered data about newly
                 Thrombosis Res Inst.,    Associated Outcomes in               diagnosed AF patients to provide information about
Wednesday,       London, UK               Patients with Atrial Fibrillation:   the clinical management and outcomes in various
Nov.7                                     The Global Anticoagulant             healthcare settings and parts of the world.
                                          Registry in the FIELD (GARFIELD)
11:55 a.m. PT,   Stuart J. Connelly,      Randomized Comparison of             Results of the Rely-able Double-blind Randomized
                 McMaster Univ.,          the Effects of Two Doses of          Trial: Long-term randomized follow-up of patients
Wednesday,       Hamilton, ON, Canada                                          receiving dabigatran – a comparison of effects of two
                                          Dabigatran Etexilate on
Nov.7                                     Clinical Outcomes over 4.3           doses on clinical outcomes
                                          Years




4

								
To top